A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation

REFERENCES

• Reading BF. Growth in world contraceptive use stalling; 215 million women's needs still unmet. Accessed 24 July 2013 from: http://www.earth-policy.org/data_highlights/2012/highlights26
   Google Scholar
• Nelson A. New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: An evolutionary step in birth control. Int J Womens Health 2010;2:99–106.
   PubMedGoogle Scholar
• Thorneycroft IH. New pills/new progestins. Infertility Reprod Med Clin N Am 2000;11:515–29.
   Google Scholar
• Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004; 70:371–7.
   PubMed Web of Science ®Google Scholar
• Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception 2006;73:235–43.
   PubMed Web of Science ®Google Scholar
• Willis SA, Kuehl TJ, Spiekerman AM, et al. Greater inhibition of the pituitary – ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100–3.
   PubMed Web of Science ®Google Scholar
• Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71–7.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Lynch AM, Hughes HD, et al. Manipulation of the pill-free interval in oral contraceptive pill users: The effect on follicular suppression. Am J Obstet Gynecol 2004;190:943–51.
   PubMed Web of Science ®Google Scholar
• Reape KZ, DiLiberti CE, Hendy CH, et al. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception 2008;77:34–9.
   PubMed Web of Science ®Google Scholar
• Sulak PJ. Continuous oral contraception: Changing times. Best Pract Res Clin Obstet Gynaecol 2008;22: 355–74.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261–266.
   PubMed Web of Science ®Google Scholar
• Aubeny E, Buhler M, Colau JC, et al. The Coraliance study: Non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care 2004;9:267–77.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89:179–83.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Parke S, Mellinger U, et al. Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracept Reprod Health Care 2013;18:274–83.
   PubMed Web of Science ®Google Scholar
• Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229–34.
   PubMed Web of Science ®Google Scholar
• Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89–96.
   PubMed Web of Science ®Google Scholar
• Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006;195:92–6.
   PubMed Web of Science ®Google Scholar
• Anderson FD, Hait H, Hsiu J, et al. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005; 71:55–9.
   PubMed Web of Science ®Google Scholar
• Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 2008;77: 162–70.
   PubMed Web of Science ®Google Scholar
• Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583–90.
   PubMed Web of Science ®Google Scholar
• Edelman A, Lew R, Cwiak C, et al. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception 2007;75:450–3.
   PubMed Web of Science ®Google Scholar
• den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59:357–62.
   PubMed Web of Science ®Google Scholar
• Sanchez-Borrego R, Garcia-Calvo C. Spanish women's attitudes towards menstruation and use of a continuous, daily use hormonal combined contraceptive regimen. Contraception 2008;77:114–7.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Paoletti AM, Lombardo M, et al. Attitudes of Italian women concerning suppression of menstruation with oral contraceptives. Eur J Contracept Reprod Health Care 2008;13:153–7.
   PubMed Web of Science ®Google Scholar
• Szarewski A, von Stenglin A, Rybowski S. Women's attitudes towards monthly bleeding: results of a global population-based survey. Eur J Contracept Reprod Health Care 2012;17:270–83.
   PubMed Web of Science ®Google Scholar
• Barnhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril 2009;91:659–63.
   PubMed Web of Science ®Google Scholar
• Barnhart K, Mirkin S, Grubb G, et al. Return to fertility after cessation of a continuous oral contraceptive. Fertil Steril 2009;91:1654–6.
   PubMed Web of Science ®Google Scholar
• Archer DF, Kovalevsky G, Ballagh SA, et al. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen. Contraception 2009;80:245–53.
   PubMed Web of Science ®Google Scholar
• Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004;9:182–93.
   PubMed Web of Science ®Google Scholar
• Spona J, Binder N, Hoschen K, et al. Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara, over three medication cycles. Eur J Contracept Reprod Health Care 2008;13:39–48.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: Results of two prospective, randomized, open-label studies. Contraception 2008;78:218–25.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Gerlinger C, Plettig K, et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003;17: 107–14.
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78:16–25.
   PubMed Web of Science ®Google Scholar
• Rible RD, Taylor D, Wilson ML, et al. Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Contraception 2009;79:182–8.
   PubMed Web of Science ®Google Scholar
• Seasonique^® (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) [prescribing information]. Sellersville, PA: Teva Branded Pharmaceutical Products R&D, Inc; 2012.
   Google Scholar